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Clopidogrel and Proton Pump Inhibitors
Influence of Pharmacological Interactions on Clinical Outcomes
and Mechanistic Explanations
Udaya S. Tantry, PHD,* Dean J. Kereiakes, MD,† Paul A. Gurbel, MD*
Baltimore, Maryland; and Cincinnati, Ohio
Dual antiplatelet therapy with aspirin and clopidogrel is associated with a signiﬁcant reduction in vas-
cular ischemic events; however, gastrointestinal bleeding events are a major concern in high-risk and
older patients. Clinical practice guidelines recommend combination therapy with proton pump inhibi-
tors (PPI) and dual antiplatelet therapy to attenuate gastrointestinal bleeding risk. In addition, high on-
treatment platelet reactivity has been associated with recurrent ischemic events. Whether or not the
pharmacological interaction between clopidogrel and PPI, which results in diminished antiplatelet ef-
fect, adversely inﬂuences clinical efﬁcacy is highly controversial and the subject of debate. Based on
largely anecdotal post-hoc analyses, the U.S. Federal Drug Administration’s and European Medicines
Agency’s recommendations discourage PPI use (particularly omeprazole) in patients treated with clopi-
dogrel. However, many American College of Cardiology/American Heart Association/Society for Cardio-
vascular Angiography and Interventions experts do not support change in clinical practice guidelines
recommendations without adequately powered, prospective, randomized clinical trial data. (J Am Coll
Cardiol Intv 2011;4:365–80) © 2011 by the American College of Cardiology FoundationI
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aThe clinical efficacy of dual antiplatelet therapy
(DAPT) combining aspirin with clopidogrel for pre-
venting recurrent cardiovascular ischemic events has
been demonstrated in a wide range of patients and
has been incorporated into clinical practice guidelines
(1). However, the recurrence of ischemic events
10%) and their association with high on-treatment
latelet reactivity (HPR) in response to adenosine
iphosphate (ADP) remain important concerns (2).
From the *Sinai Center for Thrombosis Research, Sinai Hospital of
Baltimore, Baltimore, Maryland; and †Christ Hospital, Heart and
Vascular Center/The Lindner Research Center at The Christ Hospital,
Cincinnati, Ohio. Dr. Tantry has reported that he has no relationships
to disclose. Dr. Kereiakes has received research grants from Abbott
Vascular, Amylin Pharmaceuticals, Cordis/Johnson & Johnson, Boston
Scientific, and Daiichi Sankyo, Inc.; has received consulting fees and
honoraria from Abbott Vascular, Boston Scientific, Eli Lilly and Co.,
Medpace, and REVA Medical Inc.; and is on the Speakers’ Bureau for
Eli Lilly & Co. Dr. Gurbel has received research grants from AstraZen-
eca, Boston Scientific, Medtronic, Porotola, Pozen, and Sanofi-Aventis;
and he has received consulting fees and honoraria from AstraZeneca,
Haemoscope, Porotola/Novartis, Pozen, Sanofi-Aventis, Bayer, Eli Lilly
and Co., Daiichi Sankyo, and Schering-Plough/Merck.Manuscript received November 19, 2010; revised manuscript received
December 14, 2010, accepted December 26, 2010.n addition, the cardioprotective property of pro-
onged aspirin therapy is associated with gastrointes-
inal complications including ulceration and bleeding,
hich have been attributed to topical mucosal injury
aused by inhibition of prostaglandin and to systemic
ntiplatelet effects owing to inhibition of thrombox-
ne A2 production (3). Prostaglandins are responsible
for increased mucosal blood flow, proliferation of
gastric epithelial cells, and stimulation of mucus and
bicarbonate secretion. Therefore, inhibition of pros-
taglandin synthesis by aspirin reduces the gastric
mucosa protection and makes it susceptible to gastric
ulcer formation caused by endogenous acid, pepsin,
and bile salts (3). Furthermore, inhibition of platelet
aggregation as well as growth factor release from
platelets at the site of vascular injury attenuates gastric
healing and increased susceptibility to gastrointestinal
bleeding (GIB) (4). Small bowel mucosal abnormal-
ities have been demonstrated following 100 mg aspi-
rin daily for 2 weeks as have upper gastrointestinal
endoscopic abnormalities after DAPT for 3 months
(5,6). A meta-analysis of 14 randomized trials involv-
ing 57,000 patients demonstrated a 2-fold increase
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366in major GIB in patients treated with aspirin compared with
patients treated with placebo. Although no relationship be-
tween aspirin dose and major bleeding risk was observed in this
meta-analysis, other studies have demonstrated a dose-
dependent effect of aspirin on GIB (7,8).
Unlike aspirin, clopidogrel does not directly cause gastric
injury, but its antiplatelet effects may impair healing of
existing gastric erosions and may exacerbate GI complica-
tions associated with the concomitant administration of
aspirin and nonsteroidal anti-inflammatory drugs, or in the
setting of Helicobacter pylori infection. For example, aspirin
325 mg daily (but not clopi-
dogrel 75 mg daily) for 8 days
caused direct effects on GI mu-
cosa in healthy volunteers (9). In
the CAPRIE (Clopidogrel Ver-
sus Aspirin in Patients at Risk of
Ischaemic Events) trial (10), as-
pirin monotherapy was associ-
ated with an increase in major
GIB (risk ratio [RR]: 1.45; 95%
confidence interval [CI]: 1.00 to
2.10) when compared with
clopidogrel monotherapy. In the
CURE (Clopidogrel in Unstable
Angina to Prevent Recurrent
Events) trial, aspirin mono-
therapy was associated with less
frequent major GIB when com-
pared with aspirin  clopidogrel
(RR: 0.56; 95% CI: 0.39 to 0.80)
and in the MATCH (Manage-
ment of Atherothrombosis With
Clopidogrel in High-Risk Pa-
tients) trial, clopidogrel mono-
therapy was associated with less
frequent major GIB than clopi-
dogrel  aspirin was (RR: 0.34;
95% CI: 0.23 to 0.51) (11,12).
In a Danish case control study,
more GIB complications were
observed in patients treated with
either low dose aspirin (odds
atio [OR]: 1.8; 95% CI: 1.5 to 2.1), or clopidogrel (OR:
.1; 95% CI: 0.6 to 2.1) when compared with age- and
ex-matched controls. The greatest risk of GIB occurred in
atients receiving DAPT (OR: 7.4, 95% CI: 3.5 to 15) (13).
inally, a correlation between major bleeding with subse-
uent myocardial infarction (MI), stroke, and death at 30
ays was demonstrated in both the CURRENT/OASIS-7
Clopidogrel Optimal Loading Dose Usage to Reduce
ecurrent EveNTs/Optimal Antiplatelet Strategy for Inter-
entionS) and CURE trials (14). In the CHARISMA (Clopi-
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
ATPase  adenosine
triphosphatase
CL-AM  clopidogrel active
metabolite
DAPT  dual antiplatelet
therapy
FDA  U.S. Food and Drug
Administration
GI  gastrointestinal
GIB  gastrointestinal
bleeding
HPR  high on-treatment
platelet reactivity
LD  loading dose
MACE  major adverse
cardiac event(s)
MD  maintenance dose
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PPI  proton pump inhibitors
SNPs  single nucleotide
polymorphism
VASP-PRI  vasodilator
stimulated phosphoprotein–
platelet reactivity indexogrel for High Atherothrombotic Risk and Ischemic Stabi-lization, Management, and Avoidance) trial (15), moderate
bleeding was associated with all-cause mortality (hazard ratio
[HR]: 2.55; 95% CI: 1.71 to 3.80; p 0.0001), MI (HR: 2.92;
95% CI: 2.04 to 4.18; p 0.0001), and stroke (HR: 4.20; 95%
CI: 3.05 to 5.77; p 0.0001). It should be noted that patients
who experience GIB are frequently older and have more
comorbidities.
The Rationale for Combining PPIs With
Antiplatelet Therapy
The prior observations provide a rationale for concomitant
administration of proton pump inhibitors (PPI) in patients
treated with either aspirin alone or DAPT, particularly
those at greatest risk for GIB complications (16–19). For
example, the addition of a PPI (omeprazole, lansoprazole,
pantoprazole, rabeprazole, or esomeprazole) to either aspi-
rin or thienopyridine therapy reduced the incidence of GIB
compared with either agent administered without a PPI
(RR: 0.32 and 0.19, respectively) (16). Histories of peptic
ulcer disease or cardiogenic shock were independent predic-
tors of GIB in patients treated with DAPT. Importantly,
PPI therapy administered concomitantly with DAPT or
aspirin can significantly reduce GIB (17). For example,
clopidogrel monotherapy (no PPI) was associated with a
higher incidence of recurrent ulcer bleeding than combined
aspirin plus esomeprazole treatment (8.6% vs. 0.7%, 95%
CI: 3.4 to 12.4%) in patients who were H. pylori negative
with a history of GI bleeding on low dose aspirin therapy
(18). These multiple observations suggest that the addition
of PPI as a gastroprotective agent in patients treated with
either aspirin or DAPT can mitigate the potential for GIB.
A clinical expert consensus document states that PPI
should be added to oral antiplatelet therapy in cardiovascu-
lar disease patients to reduce the risk of GIB (3). Clopi-
dogrel and PPIs are among the most widely prescribed
medications with worldwide sales of U.S. $8.6 and $26.5
billion, respectively, in 2008 (20). Furthermore, the fre-
quency of coadministration (thienopyridine with any PPI)
was 31% in the CREDO (Clopidogrel for Reduction of
Events During Observation) (21), 33% in the TRITON–
TIMI 38 (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition With Prasug-
rel–Thrombolysis In Myocardial Infarction 38) (22), 54% in
the PLATO (Platelet Inhibition and Patient Outcomes)
(clopidogrel arm) trials, and 64% in the Veterans Affairs
retrospective analysis study. Among these studies, omepra-
zole was the predominant PPI and accounted for 60% and
37% of PPI use in the VA and TRITON–TIMI 38 studies,
respectively (21–23). Based on the apparent high frequency of
coadministration, any pharmacokinetic/pharmacodynamic in-
teraction of the long-term regimens between PPIs and thien-
opyridines that could influence clinical efficacy and/or safety
must be carefully evaluated. In this regard, guidelines of the
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367U.S. Food and Drug Administration (FDA), European Med-
icines Agency, and American College of Cardiology/American
Heart Association have provided conflicting recommen-
dations regarding the concomitant use of PPI and clopi-
dogrel (3,24 –28) (Table 1). Thus, it is appropriate and
timely to review available pharmacokinetic and pharmaco-
dynamic as well as clinical information regarding interac-
tions between these medication classes.
Clopidogrel Metabolism, SNPs,
and Clinical Outcomes
Most absorbed clopidogrel (85%) is hydrolyzed by hepatic
carboxylesterase to an inactive carboxylic acid metabolite,
SR26334, and the remaining15% is converted to an active
thiol metabolite by hepatic cytochromes (CYP) in a 2-step
process (Fig. 1) (29). The parent compound is usually
undetectable in plasma at 2 h after oral administration. The
Table 1. Guidelines, Recommendations, and Policy Statements Regarding
ACCF/ACG/AHA 2008 expert consensus document (3)
“Recommendation: The use of low-dose ASA for cardioprophylaxis is associated w
reduce the risk of bleeding. For patients at risk of adverse events, gastroprotectio
The risk of UGIE increases with ASA dose escalation; thus, for the chronic phase o
“Recommendation: Substitution of clopidogrel for ASA is not a recommended stra
the combination of ASA plus PPI.”
ACC and AHA (2007) guidelines for the management of patients with unstable angin
“In UA/NSTEMI patients with a history of gastrointestinal bleeding, when ASA and
recurrent gastrointestinal bleeding (e.g., proton-pump inhibitors) should be prescr
“Clopidogrel 75 mg daily (preferred) or ticlopidine (in the absence of contraindica
contraindicated or not tolerated because of hypersensitivity or gastrointestinal int
of Evidence: A).”
U.S. FDA update to clopidogrel labeling (25)
”The concomitant use of omeprazole and clopidogrel should be avoided because
risk for heart attacks or strokes, who are given clopidogrel to prevent blood clots,
omeprazole or the OTC form (Prilosec OTC).
 Separating the dose of clopidogrel and omeprazole in time will not reduce this
 At this time, FDA does not have sufﬁcient information about drug interactions
recommendations about their coadministration. Healthcare professionals and patie
European Medicines Agency public statement on possible interaction between clopi
“Taking all the data into account, the Agency’s Committee for Medicinal Products
recommended that the product information for all clopidogrel-containing medicin
medicines unless absolutely necessary. Accordingly, the marketing authorization h
applications to amend the product information.
Furthermore, CHMP recommended that further information is needed in relation to
implications of genetic variation which results in a small proportion of individuals
active form, regardless of interactions with other medicines.”
International Consensus Upper Gastrointestinal Bleeding Conference Group. Internat
upper gastrointestinal bleeding (27)
“In patients with previous ulcer bleeding who require cardiovascular prophylaxis,
combined with a PPI” and “Patients with upper GIB who require secondary cardio
prophylaxis outweigh gastrointestinal risks (usually within 7 days); ASA plus PPI th
2009 focused updates: ACC/AHA guidelines for the management of patients with ST
Foundation/American Heart Association Task Force on Practice Guidelines (28).
“The writing committee concluded that additional data, notably randomized trial
recommendation can be made about the use of dual antiplatelet therapy with PP
ACC American College of Cardiology; ACCF American College of Cardiology Foundation; ACG
FDA Food and Drug Administration; GIB gastrointestinal bleeding; NSTEMI non–ST-segmeangina; UA/NSTEMI unstable angina/non–ST-segment elevation myocardial infarction; UGIE upper gathiophene ring is first oxidized to 2-oxo-clopidogrel and to
an active metabolite (CL-AM), R-130964, in the second
step. This highly unstable CL-AM binds covalently and
specifically to the platelet ADP-binding site in the P2Y12
receptor when platelets pass through the hepatic circulation.
Recent studies indicate that the CYP2C19, CYP1A2,
CYP2B6 isoenzymes are responsible for the first step,
whereas CYP2C19, CYP2C9, CYP2B6, and CYP3A4 are
responsible for the second step. As noted, CYP2C19 con-
tributes substantially to both steps, whereas CYP3A4 con-
tributes substantially to the second step (30).
Multiple lines of evidence suggest that variable and
insufficient CL-AM generation following clopidogrel ad-
ministration are the primary explanations for clopidogrel
response variability and nonresponsiveness, respectively.
Variable levels of CL-AM generation may be explained by
multiple genetic, environmental, and clinical factors. In
se in Patients Treated With Oral Antiplatelet Therapy
- to 4-fold increase in UGIE risk. Enteric-coated or buffered preparations do not
ld be prescribed.
py, doses 81 mg should not be routinely prescribed.”
o reduce the risk of recurrent ulcer bleeding in high-risk patients and is inferior to
–ST-segment elevation myocardial infarction (24)
ogrel are administered alone or in combination, drugs to minimize the risk of
oncomitantly (Classic Journal, Level of evidence: B).”
should be given to patients recovering from UA/NSTEMI when ASA is
e (but with gastroprotective agents such as proton-pump inhibitors) (CLASS, Level
effect on clopidogrel’s active metabolite levels and anticlotting activity. Patients at
ot get the full protective anticlotting effect if they also take prescription
interaction.
en clopidogrel and PPIs other than omeprazole and esomeprazole to make speciﬁc
ould consider all treatment options carefully before beginning therapy.”
and proton-pump inhibitors (26)
man Use (CHMP) and its Pharmacovigilance Working Party (PhVWP) have
uld be amended to discourage concomitant use of PPI and clopidogrel-containing
for the clopidogrel-containing medicines will shortly be submitting variation
ibition of clopidogrel metabolism by other medicines, and in relation to the
lled “CYP2C19 poor metabolizers”) being unable to fully convert clopidogrel to its
onsensus recommendations on the management of patients with nonvariceal
ld be recognized that clopidogrel alone has a higher risk for rebleeding than ASA
r prophylaxis should start receiving ASA again as soon as cardiovascular
is preferred over clopidogrel alone to reduce bleeding.”
ion myocardial infarction: a report of the American College of Cardiology
at have been peer reviewed and published, are needed before an ofﬁcial
e setting of ACS.”
rican College of Gastroenterology; AHA American Heart Association; ASA acetylsalicylic acid;
tion myocardial infarction; OTC over the counter; PPI proton pump inhibitor; UA unstablePPI U
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368addition, intestinal p-glycoprotein transporter and its inhib-
itors (including omeprazole) may play a role in clopidogrel
absorption (31). Moreover, a relationship between the
p-glycoprotein gene polymorphisms and the occurrence of
adverse ischemic events has been demonstrated in patients
treated with dual antiplatelet therapy (32–34).
Functional variability in hepatic P450 isoenzyme activity
owing to single nucleotide polymorphisms (SNPs), drug-
drug interactions, and other factors may affect clopidogrel
metabolism and its clinical efficacy. A diminished pharma-
codynamic response to clopidogrel has been observed with
coadministration of PPIs, lipophilic statins, calcium channel
blockers, and warfarin that are metabolized by the
CYP2C19, CYP3A4, and CYP2C9 isoenzymes, respectively
(35–38). Moreover, cigarette smoking and coadministration
of Saint John’s wort or rifampin are known to augment the
antiplatelet response to clopidogrel through activation of
CYP1A2 and CYP3A4, respectively (36,39,40). The clinical
consequences of these pharmacodynamic interactions remain
controversial. Furthermore, increased body mass index, diabe-
tes mellitus (particularly in the contexts of elevated serum
fibrinogen, poor glucose control, or diminished renal function)
and the extent of existing coronary disease may be associated
with increased baseline platelet reactivity and a diminished
Figure 1. Clopidogrel Metabolism and Sites of Drug-Drug Interactions and
Clopidogrel response variability is a pharmacokinetic problem primarily inﬂuen
metabolite. Clopidogrel absorption may be affected by polymorphism of the A
drug-drug interactions (DDIs), single nucleotide polymorphisms (SNPs), and ot
from Bonello et al. (2).antiplatelet response to clopidogrel (41–43). wRecent studies have evaluated the relationship between
single SNPs of the gene encoding CYP2C19 isoenzymes
with clopidogrel response variability and clinical outcomes
(44–48). It remains uncertain whether other factors asso-
ciated with a diminished clopidogrel response may be
additive to SNPs in further reducing the antiplatelet effect
of clopidogrel and thus, potentially, its clinical efficacy in
reducing ischemic events. Of at least 25 SNPs for the gene
encoding the CYP2C19 isoenzyme (49), the most frequent
and widely analyzed include *2, which has been associated
with a complete absence of 2C19 activity (allele frequency
15% in Caucasians and African Americans and 30% in
Asians) and *17, which has been associated with increased
expression and enzyme function (allele frequency 15% in
Caucasians and African Americans and 4% in Asians).
The *3, *4, *5, and *8 variants are less frequently observed
loss of function alleles (50).
Based on ADP-induced platelet aggregation measure-
ment to reflect clopidogrel responsiveness in the GWAS
(Genome Wide Association Study), Shuldiner et al. (45)
identified a 13-SNP cluster (within a flanking CYP2C18-
2C19-2C9-2C8 cluster of 1.5 megabases on 10q24) out of
400,000 SNPs that was associated with 70% of clopi-
dogrel response (p  107) and from which CYP2C19*2
ic Polymorphisms
y cytochrome P450 (CYP) isoenzyme activity in the generation of the active
gene. The activity of the hepatic cytochrome isoenzymes are inﬂuenced by
tors such as smoking and caffeine consumption. Modiﬁed, with permission,Genet
ced b
BCB1
her facas the major SNP accounting for 12% of the 10q24
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369associated signal. In the same study, carriers of the
CYP2C19*2 genotype who had undergone percutaneous
coronary intervention (PCI) experienced higher cardiovas-
cular event rates than noncarriers did (HR: 2.42; p  0.02)
(45). In healthy volunteers, a 32.4% relative reduction (p 
0.001) in plasma CL-AM and a 25% relative reduction in
mean platelet aggregation (p  0.001) was observed in
carriers of at least 1 CYP2C19 reduced-function allele
compared with noncarriers (46). Numerous studies have
correlated adverse clinical outcomes with CYP2C19*2 carrier
status (44–48,50–53). Among patients with acute coronary
syndromes who had PCI and were treated with clopidogrel
in the TRITON–TIMI 38 trial, carriers of a 2C19 reduced-
function allele had an increase in primary endpoint events
(cardiovascular death, nonfatal MI, or nonfatal stroke) (HR:
1.53; p  0.04) and stent thrombosis (HR: 3.09; p  0.02)
compared with noncarriers (46). Similarly, compared with
2C19 wild-type homozygotes, 2C19*2 carriers were dem-
onstrated to have an increased incidence of stent thrombosis
to 30 days (HR: 3.81; p  0.007) (15). These investigators
also demonstrated that 2C19*17 allele carriers had lower
levels of ADP-induced platelet aggregation (p 0.039) and
higher bleeding risk during clopidogrel treatment compared
with wild-type carriers (p  0.01) (51). Meta-analyses by
both Hulot et al. (52) and Mega et al. (53) have demon-
strated that carriers of the 2C19*2 allele, when compared
with noncarriers, have an increased risk for major adverse
cardiac events (MACE) including death and stent throm-
bosis, and risk was independent of baseline cardiovascular
risk. In the Hulot et al. (52) meta-analyses, an increased risk
for MACE and mortality was also observed in PPI users (vs.
nonusers) particularly those with high baseline cardiovascu-
lar risk. Conversely, in the recently published genetic
substudies of the CHARISMA (54), CURE (55), and
ACTIVE A (Effect of Clopidogrel Added to Aspirin in
Patients With Atrial Fibrillation) (55) trials, there was no
association of CYP2C19*2 allele with adverse clinical out-
comes in clopidogrel-treated subjects. Potential explana-
tions for these apparent discrepant observations include the
lower use of PCI with stenting in the CURE trial (14.5%)
as well as the relatively lower-risk populations enrolled into
the ACTIVE A and CHARISMA trials (nonacute coro-
nary syndrome, non-PCI/stenting) (56).
Thienopyridines may inhibit CYP isoenzymes as demon-
strated in in vitro studies using human liver microsomes and
recombinantly expressed P450 isoforms. Both clopidogrel
and ticlopidine were associated with time- and con-
centration-dependent inhibition of CYP2B6 and to a lesser
extent, CYP2C19 (57). A weak inhibitory effect of 2-oxo-
clopidogrel, prasugrel, and R-95913 (active metabolite of
prasugrel) was also observed (58). Inhibition of CYP2C19
activity by ticlopidine was directly proportional to the level
of baseline activity and, thus, was most evident in normal
(*1/*1) metabolizers. Repeated ticlopidine dosing was asso- Cciated with an increase in omeprazole concentrations in
rapid metabolizers but not in the poor metabolizers (59,60).
The influence of clopidogrel on CYP2C19-dependent
omeprazole metabolism was evaluated in healthy volunteers
who received either placebo or clopidogrel (300-mg load, 75
mg/day for 3 days) coadministered with omeprazole (40
mg/day). A significant increase (mean 30%) in plasma
omeprazole and a significant decrease (mean 24%) in plasma
5-hydroxyomeprazole were observed in rapid metabolizers
(*1/*1 allele) but not in poor metabolizers (*2/*2 allele) (61).
This study demonstrated that clopidogrel inhibited
CYP2C19-mediated hydroxylation of omeprazole in rapid
metabolizers but had no effect on CYP3A4-catalyzed sul-
foxylation of omeprazole. Thus, omeprazole metabolism
may be shifted to CYP3A4 in poor (CYP2C19) metabo-
lizers or in the presence of a CYP2C19 inhibitor such as
clopidogrel (61).
PPIs
Mechanism of action and metabolism. Proton pump inhib-
tors are benzimidazole-derivative prodrugs whose absorp-
ion from the bowel is influenced by the p-glycoprotein
ransporter. The H/K-adenosine triphosphatase
ATPase) present in the canalicular membrane of gastric
arietal cells secretes hydrochloric acid and a proton is
xchanged for potassium with ATP breakdown. Following
bsorption, PPIs undergo activation and the activated cyclic
ulfonamide covalently binds to the extracytoplasmic cys-
eine residues of H/K-ATPase and irreversibly inhibits
/K-ATPase pump activity/gastric secretion. Because
f the short plasma half-life (1 to 2 h) of PPIs and
ontinuous activation of inactive pumps, up to 3 days are
equired to achieve maximum acid suppression by PPIs (62).
lthough all PPIs are highly effective in inhibiting gastric
cid secretion, pharmacokinetic and pharmacodynamic dif-
erences may influence clinical effectiveness as well as the
otential for drug-drug interactions (62). Although the
ioavailability of pantoprazole, lansoprazole, and rabepra-
ole are similar, plasma concentrations of omeprazole in-
rease 1.5- to 2-fold and of esomeprazole 3-fold following 5
ays of therapy compared with day 1 (63).
Effects of PPIs on CYP-isoenzyme activity and drug-drug
interactions. All PPIs, except for rabeprazole, are exten-
ively metabolized by and competitively inhibit CYP2C19
nd CYP3A4 (60). Lansoprazole and omeprazole appear to
e the strongest (Ki  0.4 to 1.5 mol/l and 2 to 6 mol/l,
respectively), whereas pantoprazole is the weakest inhibitor
(Ki  14 to 69 mol/l) of CYP2C19. The observation of
ignificant interaction between PPIs and other CYP2C19
etabolized drugs such as diazepam, phenytoin,
-warfarin, and clopidogrel is not surprising in that 70%
f all therapeutic drugs are metabolized by CYP3A4 and
YP2C219 isoenzymes (62) (Fig. 2). Moreover, a significant
f
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370association between omeprazole metabolism and CYP2C19
genotype (metabolizer status, loss or gain of function alleles)
exists (62,64).
The CYP2C19*2 reduced function allele is associated with
poor metabolism of omeprazole and other drugs such as
diazepam and phenytoin (65). In addition, other CYP-
isoenzymes such as CYP3A4 may become more important in
CYP2C19*2 poor metabolizers or in the presence of potent
CYP2C19 inhibitors such as clopidogrel (61,65). Interest-
ingly, the coadministration of drugs with high affinity for
CYP3A4 (ketoconazole or clarithromycin) inhibits omepra-
zole metabolism and is associated with increased plasma
omeprazole concentrations in poor as well as extensive
CYP2C19 metabolizers. Conversely, coadministration of
ginkgo biloba or St John’s wort (CYP2C19 inducers) en-
hances the metabolism of omeprazole (62). Rabeprazole,
which is mainly metabolized through nonenzymatic reduc-
tion to a thioether compound, has the least inhibitory effect
on CYP isoenzyme activities (62). A recent meta-analysis
suggests that the efficacy of omeprazole but not rabeprazole
in the treatment of H. pylori infection depends on CYP2C19
gene polymorphism and metabolizer status (66). In addi-
tion, in vitro studies demonstrated that PPIs could inhibit
the p-glycoprotein mediated efflux of digoxin (67). Finally,
Figure 2. Omeprazole Metabolism, Mechanism of Action, and Sites of Drug
After absorption, omeprazole undergoes activation (protonation) and the activ
pump activity/gastric secretion. Omeprazole is extensively metabolized by and
pathway involves its conversion by CYP2C19 to inactive 5-hydroxyomeprazole
second step. However, omeprazole ﬁrst metabolized by CYP3A4 to omeprazole
allele carriers or subjects treated with drugs that are mainly metabolized by 2C19both CYP2C19 and p-glycoprotein genetic polymorphisms pmay influence drug-drug interactions and the pharmacoki-
netic/pharmacodynamic properties of PPIs, which in turn
may influence clinical outcomes related to gastric acid
suppression and/or H. pylori eradication (66–68).
Drug-Drug Interactions Between
Clopidogrel and PPIs
Pharmacokinetic and pharmacodynamic interactions. Mul-
tiple pharmacodynamic studies have demonstrated the in-
fluence of PPI treatment (particularly omeprazole) on clopi-
dogrel antiplatelet effects (35,62,69–80) (Table 2). In a
double-blind, randomized controlled study, PCI patients
treated with aspirin (75 mg/day) and clopidogrel (300-mg
loading dose [LD]  75-mg/day maintenance dose [MD])
were randomly assigned to receive either omeprazole (20
mg/day) or placebo for 7 days. Omeprazole reduced clopi-
dogrel antiplatelet effect (vasodilator stimulated phospho-
protein–platelet reactivity index [VASP-PRI]: 39.8% pla-
cebo vs. 51.4% omeprazole, p  0.0001) at 7 days but not
on day 1. Moreover, the prevalence of a poor clopidogrel
response (defined by a VASP-PRI 50%) was higher
ollowing omeprazole than placebo (60.9% vs. 26.7%, re-
pectively, p  0.0001) (35). Similarly, in a randomized
Interactions and Genetic Polymorphisms
yclic sulfonamide irreversibly inhibits H/K–adenosine triphosphatase
etitively inhibits CYP2C19 and CYP3A4. The major omeprazole metabolism
metabolized to inactive omeprazole hydroxy sulfonate by CYP3A4 in the
ate and further to omeprazole hydroxy sulfonate in the 2C19 loss-of-function
s clopidogrel, diazepam, and phenytoin. Abbreviations as in Figure 1.-Drug
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371coadministration of clopidogrel (600-mg LD  75-mg/day
D for 14 days) with omeprazole (20 mg/day) resulted in
ecreased platelet inhibition (measured by the VerifyNow
2Y12 assay) at day 14 (p  0.048) but not at 1 or 7 days
(70). In a post hoc subgroup analysis of the PRINCIPLE–
TIMI 44 (The Prasugrel in Comparison to Clopidogrel for
Inhibition of Platelet Activation and Aggregation–
Thrombolysis In Myocardial Infarction 44) trial, coadmin-
istration of PPI with clopidogrel reduced platelet inhibition
at 2, 6, and 18 to 24 h after 600-mg clopidogrel LD with a
trend toward reduction in platelet inhibition following
150-mg/day MD for 15 days compared with clopidogrel
monotherapy. Prasugrel-mediated platelet inhibition was
also reduced both acutely and at 15 days by PPI coadmin-
istration compared with prasugrel alone and the proportions
of nonresponders (defined by29% inhibition of 20 mol/l
ADP-induced aggregation) to both clopidogrel and prasu-
grel were increased by PPI coadministration (71).
A differential response between various PPI and clopi-
dogrel has been suggested. For example, using the Multi-
plate analyzer (Multiplate, Munich, Germany), Sibbing et
al. (72) observed that patients coadministered omepra-
zole, but not pantoprazole or esomeprazole, had higher
residual platelet aggregation while on clopidogrel therapy
(p  0.001). In addition, the prevalence of a poor clopi-
dogrel response (defined as an arbitrary unit [AU]  min
456) was higher in patients treated with omeprazole (33%
vs. 19% without, p 0.008). However, other factors such as
diabetes, body mass index, renal insufficiency, and smoking
(in addition to omeprazole treatment) were independent
predictors of antiplatelet response to clopidogrel treatment
(72). In a crossover study involving healthy volunteers
treated with single doses of either clopidogrel (300 mg) or
prasugrel (60 mg), the coadministration of lansoprazole did
not alter platelet inhibition by prasugrel, but a trend toward
reduction in clopidogrel-mediated platelet inhibition was
observed that was most pronounced in clopidogrel respond-
ers (74). Other studies have suggested that the PPI-
clopidogrel interaction to reduce clopidogrel-mediated
platelet inhibition is less evident following pantoprazole or
rabeprazole than omeprazole (64,75). Furthermore,
CYP2C19 metabolizer status may significantly influence the
magnitude of PPI-clopidogrel interaction. For example, a
reduction in antiplatelet effect of clopidogrel effect was
observed in rapid metabolizers (genotype *1/*1) adminis-
tered either omeprazole (p  0.015) or rabeprazole
(p 0.035) but not in decreased metabolizers (*2 or *3 allele
arriers). Nevertheless, clopidogrel-induced inhibition of
latelet aggregation remained lower in decreased versus
apid metabolizers irrespective of concomitant or spaced
PI administration (p  0.0001), and there were no
lopidogrel poor responders among the rapid metabolizer
ohort (64).Finally, 4 randomized, placebo-controlled, crossover
omparison studies involving 282 healthy volunteers were
onducted to analyze the PPI-clopidogrel interaction. Sub-
ects received either omeprazole (80-mg/day delayed-release
ormulation) or pantoprazole (80 mg/day) and clopidogrel
300-mg LD  150-mg/day MD) was administered either
ynchronously (with PPI) or separately (76). A synchronous
with omeprazole) clopidogrel 600-mg LD  150-mg/day
D was also assessed. Unchanged plasma clopidogrel levels
ncreased (19% at day 2, 37% to 51% at day 5) and CL-AM
evels decreased (45% to 55% at day 2, 40% to 54% at day 5)
rrespective of clopidogrel LD or the timing of omeprazole
dministration. This observation argues against the presence
f a drug-drug interaction at the p-glycoprotein transporter
evel or related to gastric pH effects. During omeprazole
oadministration, platelet aggregation (5 mol/l ADP)
ncreased by 11% to 16% on day 1 and 6% to 8% on day 5
n concert with a decrease in CL-AM levels. Similarly,
ASP-PRI increased on days 1 (17% to 20%) and 5 (19%
o 27%) of omeprazole treatment. During pantoprazole
oadministration, CL-AM decreased (14% to 20%) whereas
oth platelet aggregation and VASP-PRI increased by 4.3%
nd 3.9% to 5.1%, respectively. These observations sug-
est: 1) the PPI-clopidogrel interaction is more promi-
ent for omeprazole than pantoprazole; 2) a reduction in
L-AM level is the primary explanation for the PPI-
lopidogrel interaction; and 3) staggering the time course
f clopidogrel-omeprazole dosing does not influence the
nteraction. However, these studies were performed with-
ut aspirin coadministration (which has dose-dependent
ffects on platelet function) and the dose of omeprazole
80 mg/day omeprazole for 5 days before clopidogrel or
lacebo dosing) was 2 to 4 times that commonly pre-
cribed clinically (76).
However, in a study of healthy volunteers administered
meprazole (40-mg/day delayed-release formulation) ei-
her concomitantly or staggered by 8 to 12 h with
lopidogrel (600-mg LD and 75-mg/day MD), no dif-
erence in clopidogrel-induced antiplatelet effect (light
ransmittance aggregometry, VASP-PRI, VerifyNow
2Y12) was observed following the loading dose or at 1 week
of maintenance therapy (77). Either synchronous or spacing
omeprazole coadministration strategies resulted in higher
VASP-PRI levels compared with clopidogrel monotherapy.
Finally, the pharmacodynamic interaction between clopi-
dogrel (300-mg LD  75-mg/day MD) and PA32540, a
novel combination drug (325 mg enteric-coated aspirin 
40 mg immediate-release omeprazole) was evaluated in
healthy volunteers using both synchronous as well as stag-
gered (12 h apart) dosing regimens. In this study, staggered
clopidogrel and PA32540 administration was associated
with a greater clopidogrel-induced antiplatelet effect (re-
duced drug-drug interaction) compared with synchro-
nous administration (78). Variations in CYP2C19 genotype,
Table 2. Pharmacodynamic Studies Demonstrating the Relation of Clopidogrel Antiplatelet Response With PPI Use
First Author (Ref. #) Patients (n) Treatment Method Results Comments
Gilard et al. (35)
Randomized, double-blind,
placebo controlled study
Elective PCI (124) OMZ 20 mg (n  64) or
placebo (n  60); CLP
300-mg LD  75-mg MD,
ASA 75 mg MD for 7 days
VASP-PRI
Day 1
Day 7
Day 1  83.9 4.6% vs.83.2 5.6%; p  NS
Day 7  51.4 16.4% vs. 39.8 15.4%;
p  0.001 50% PRI  60.9% vs. 26.7%;
p  0.001
Randomized study
Omeprazole effect was observed
on day 7, more nonresponders
Gilard et al. (69)
Observational study
High risk coronary
angiography (105)
ASA; clopidogrel, PPI VASP-PRI
48 h after antiplatelet
therapy
Mann-Whitney U test
—no difference for statins, ACEI, ANG II
antagonists and beta blockers
—with (n  24) and without PPI (n  81)
PRI  61.4 23.2% vs. 49.5 16.3%;
p  0.007
Observational study
Yun et al. (70)
Crossover study
Healthy volunteers (n  20) 75 mg/day CLP or placebo
for 14 days followed by
75 mg/day CLP or 20 mg
OMZ for 14 days
VerifyNow P2Y12 assay 1 and 7 days—no change
14 days PRU: OMZ, 281.3 54 vs.
240 72.2, p  0.048
14 days % inhibition: OMZ 22.7 29.9 vs.
35.1 18.7, p  0.014
O’Donoghue et al. (71)
Post-hoc, nonrandomized subgroup
analysis of PRINCIPLE–TIMI 44 study
Planned PCI (201) 600 mg/150 mg CLP
(n  22)  PPI vs. CLP alone
(n  71) 60 mg/10 mg
PRS  PPI (n  25) vs.
PRS alone (n  77)
IPA 20 mol/l ADP LTA CLP  PPI: signiﬁcantly decreased IPA at 2, 6,
2–24 h and 15 days;
p  0.003, 0.02, 0.03, and 0.06,
respectively)
No information on PPI; PPI
patients were not randomized;
study was not powered to
detect the difference in IPA
0.5, 2, 6, 20–24 h and 15 days.
Nonresponders (20% IPA)
at 6 h and 15 days
Nonresponders: 6 h: 50% vs. 18.2%
p  0.009 and 15 days: 50% vs. 7.9%,
p  0.012 PRS  PPI: signiﬁcantly
decreased IPA at 0.5, 6, and 15 days;
p  0.009, 0.054, and 0.01 respectively) 6 h:
0% vs. 0% p  NS and 15 days: 10% vs.
0%, p  0.025)
Sibbing et al. (72)
Cross-sectional observational study
Controlled PCI (n  1,000) Pts on median 7 months
75-mg/day CLP treatment
No PPI  732, PNT  158,
OMZ  64, ESM  74
At hospital admission
Multiplate analyzer: 6.4 mol/l
ADP-induced AU  min
Nonresponders  upper
quintile (456 AU  min)
No PPI  220 AU  min
OMZ  295.5AU  min (p  0.001)
Nonresponders: OMZ  32.8% vs. 19.1
(p  0.008)
PNT  226 AU  min (p  0.69)
ESM  209.0 AU  min (p  0.88)
Zuren et al. (73)
Observational study
CAD PCI (n  1,425) 1 week PPI use before
60-mg CLP LD OMZ  36,
PNT  108, ESM  280
20 mol/l ADP  LTA  20 h
after LD
No PPI vs. PPI; 40 16.6 vs. 41.1 17.4
p  0.005
Similar effect with all PPIs, PPI,
age, BMI, ACEI are associated
with HPR (49%)
Continued on next page
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373which may have influenced the clopidogrel-omeprazole
interaction, were not assessed in these later studies.
Coadministration of PPI With
Clopidogrel and Clinical Outcomes
Multiple epidemiological studies have suggested that the
concomitant administration of PPI with clopidogrel may be
associated with adverse clinical events (71,79–89) (Table 3).
For example, the potential interaction between clopidogrel
and PPIs was evaluated by a case-control study of patients
who filled prescriptions for clopidogrel within 3 days of
hospital discharge following acute MI. After extensive
multivariate adjustment, the concurrent use of PPIs with
clopidogrel was associated with an increased incidence of
recurrent MI to 90 days (adjusted odds ratio [AOR]: 1.27)
(80). However, the lack of data on patient compliance with
antiplatelet therapy as well as the inability to account for
ethnicity and CYP2C19 gene polymorphisms limits the
reliability of this observation (81).
In a retrospective analysis of patients receiving clopi-
dogrel after hospital discharge for acute coronary syndrome,
multivariate analysis identified coadministration of PPI and
clopidogrel therapy (vs. clopidogrel monotherapy) to be
associated with an increased risk for death or rehospitaliza-
tion (AOR: 1.25) as well as hospitalization for recurrent
acute coronary syndrome or revascularization (AOR: 1.86
and 1.49, respectively) (82). In the clopidogrel Medco
Outcomes study of clopidogrel-treated patients following
coronary stenting, MACE to 1 year was increased by 50% in
patients receiving concomitant PPI therapy compared with
those who were not (83). This relative risk persisted
following statistical adjustment for baseline differences in
age, sex, and comorbidities. Moreover, the effect of PPI was
more pronounced (AOR: 1.86) among patients with a
history of cardiovascular events before stenting. Although
the risk associated with PPI among clopidogrel-treated
patients persisted regardless of PPI type (omeprazole, es-
omeprazole, pantoprazole, and lansoprazole), no risk was
apparent (PPI vs. no PPI) in the absence of concomitant
clopidogrel therapy. Conversely, in a retrospective analysis
of the CREDO trial, primary endpoint events at 28 days
(death, MI, and urgent target vessel revascularization) and 1
year (death, MI, and stroke) were increased in patients
receiving PPIs at study baseline, regardless of their subse-
quent randomized clopidogrel (vs. placebo) treatment allo-
cation (84). Treatment with clopidogrel reduced cardiovas-
cular events through 1 year to a similar degree whether or
not patients were receiving concomitant PPI. No influence
of PPI on clopidogrel clinical efficacy was observed (p 
.69 for interaction of PPI and randomized treatment).
inally, in a Danish nationwide cohort study of patients
ospitalized for MI, an 30% increase in risk for cardio-vascular death or rehospitalization for MI or stroke wasT S C A
IP p V
Table 3. Studies Demonstrating the Influence of Coadministration of PPI on Clinical Efficacy of Clopidogrel Treatment
First Author (Ref. #) Patients (n) Treatment End point Results Comments
O’Donoghue et al. (71)
Post-hoc, nonrandomized
subgroup of TRITON–TIMI 38
study
ACS-planned PCI (n  13,608) PRS: 60-mg LD  10-mg MD CLP:
300-mg LD  75-mg MD
PPI  33.3% pts, PNT  1,844,
OMZ  1,675, ESM  613,
LNZ  441, RBR  66
Pts with and without reduced
function 2C19 allele
1-year composite of CV
death, nonfatal MI, or
nonfatal stroke (adjusted
for 28 variables)
Adjusted HR
CLP  0.94, 95% CI: 0.80–1.11
PRS  1.00, 95% CI: 0.84–1.20.
No effect of individual PPI.
Reduced function allele CLP pts
without and with PPI 10.2%
vs. 13% HR: 0.76. Reduced
function allele PRS pts
without and with PPI 7.4% vs.
9.9% HR  0.81.
PPI use determined at the time of
randomization and at follow-up
points.
Pezalla et al. (79)
Retrospective cohort
65-year-old pts treated with
CLP
No PPI (n  4,800), low PPI exposure
(n  712), high PPI exposure
(n  3,345)
1-year MI No PPI  1.38%, Data corrected only for comorbidities
Low PPI  3.08%, High PPI 
5.03%; p  0.005
Juurlink et al. (80)
Nested-control study
65-year-old UA pts treated
with CLP following MI
(n  13,636)
PPI vs. no PPI, 734 (PPI  194) pts
readmitted for MI, controls  2,057
(PPI  424)
90-days and 1-year acute MI Current use of PPI, OR: 1.27 Data adjusted for demographic
variables, concomitant
medications, and comorbidity.
CYP2C19 metabolized PPIs:
OR  1.40. PNT (Non-
CYP2C19 metabolized):
OR: 1.02
Ho et al. (82)
VA hospital database
retrospective study
ACS pts taking CLP
(n  8,205)
63.9%  prescribed PPI at discharge
36.1%  no PPI
Death or RH Adjusted or for death or RH PPI
vs. no PPI: 1.25, RH  1.86,
revascularization  1.49,
death  0.91.
Risk of confounding variables at
baseline were adjusted for
analysis.
OMZ (59.7%)  1.24,
RBR (2.9%)  2.83
Each 10% increase in the time taking
CLP  PPI was associated with
higher risk for death or
revascularization (OR  1.07)
Kreutz et al. (83)
Retrospective (Medco) study
Previous PCI (n  16,690) Pts never made PPI prescription over
1-year post-stenting (n  9,862)
Pts with PPI (6,828)
1-year MACE
hospitalization CV death for
stroke/TIA, ACS, or
coronary
revascularization.
MACE  17.9%, vs. 25.1%
HR  1.51; 95% CI: 1.39–1.64,
p  0.0001. HR for OMZ 
1.39, ESM  1.57, PNT 
1.61, LNS  1.39
No increased risk of PPI in patients
not treated with CLP compared
with no PPI. (20.8% no PPI vs. PPI
24.8%; HR  1.19; 95% CI:  0.84–
1.70)
Dunn et al. (84)
Retrospective cohort of CREDO
randomized trial
Undergoing or high likelihood
of PCI (n  1,053)
CLP  ASA for 4 weeks vs. 1 year.
PPI  CLP  176 vs. CLP  877
PPI  190 vs. no PPI  873
1-year death, MI, or stroke CLP  PPI vs. CLP; OR: 1.63,
p  0.043
PPI vs. no PPI; OR  1.55,
p  0.035
Continued on next page
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Table 3. Continued
First Author (Ref. #) Patients (n) Treatment End point Results Comments
Kwok et al. (86)
Meta-analysis
23 studies
(n  93,278)
CLP  PPI MACE  19 studies
MI  17 studies
No risk association in propensity-
matched or randomized trials.
Observational studies adjusted for
confounders. MACE, OR  1.44,
p  0.0001, Mortality  1.04
Substantial heterogeneity.
Overall, CLP and PPI use may be
associated with adverse CV events
and MI, but no effect on mortality.
Siller-Matula et al. (87)
Meta-analysis
Randomized trials
(TRITON–TIMI 38,
COGENT, CREDO)
CLP  PPI MACE, MI, death MACE: RCT: OR  1.08, p  0.60
Non-RCT: OR  1.33, p  0.0004
MI: RCT: OR  0.98, p  0.79 Non-RCT:
OR  1.27, p  0.07 Death: RCT:
OR  68, p  0.04 Non-RCT:
OR  0.95, p  0.30
Investigators conclude that higher rate
of comorbidities in pts with CLP 
PPI might be major cause for
observed worse clinical outcome
rather than effect of PPI.
Rassen et al. (88)
Retrospective cohort
65 years old, PCI, or
hospitalized for ACS
(n  18,565)
CLP  PPI 6-month MI or death Propensity score adjusted ratio for death
or MI  1.22, death  1.20,
revascularization  0.97.
Demonstrated only a modest effect
(risk unlikely to exceed 20%).
Bhatt et al. (89)
Double-blind randomized
AMI, UA pts undergoing
stenting
(n  3,267)
CLP  OMZ delayed-release
combination product)
CLP  placebo
Primary:
GI events
Secondary: CV death, nonfatal
MI, CABG, or PCI or stroke
OMZ has fewer GI events
HR  0.55, p  0.007)
No difference in
CV events (HR  1.02).
Combination drug properties unknown.
Premature termination. No complete
follow-up. Low risk of confounding
variables owing to speciﬁc inclusion
and exclusion criteria.
ACS acute coronary syndrome; CABG coronary artery bypass grafting; COGENTClopidogrel and theOptimizationofGastrointestinal Events; CREDOClopidogrel for Reductionof EventsDuringObservation; CV cardiovascular; GIgastrointestinal; HRhazard
ratio;MACEmajor adverse cardiac events;MImyocardial infarction;ORodds ratio; RCT randomized clinical trial; RH rehospitalization; RBR rabeprazole; TIA transient ischemic attack; TRITON–TIMI 38 Trial toAssess Improvement in TherapeuticOutcomes
by Optimizing Platelet Inhibition With Prasugrel; other abbreviations as in Tables 1 and 2.
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376observed in patients treated with PPI and clopidogrel
compared with clopidogrel alone (85). However, a similar
risk was also observed with PPI in patients not receiving
concomitant clopidogrel and was attributed to unmeasured
cofounders. No interaction was demonstrated between PPI
and clopidogrel.
Discrepancy in the reported clinical relevance of a poten-
tial PPI-clopidogrel interaction may in part be explained by
recent meta-analyses (86,87) that support the concept that
the presence and magnitude of relative hazard related to PPI
in clopidogrel-treated patients depends on study type and
method of analysis. The relative risk ratio for adverse
outcomes related to PPI progressively diminishes from
crude raw data to statistically adjusted observational studies
and finally to propensity score adjusted analyses or random-
ized trials. These studies conclude that evidence for a
meaningful clopidogrel-PPI interaction on cardiovascular
outcomes is inconsistent and that no definite evidence exists
for an effect on mortality. This premise finds support in a
retrospective population-based study of elderly PCI patients
that concluded that the relative risk attributable to PPI
failed to meet conventional thresholds for statistical signif-
icance and did not exceed 20% (88).
Although concern regarding concomitant PPI-thieno-
pyridine administration persists and has been heightened by
a FDA communication, this concern has not been substan-
tiated to date by adequately powered, large-scale random-
ized trials with clinical endpoints. In the recently reported
COGENT (Clopidogrel and the Optimization of Gastro-
intestinal Events) trial, 3,873 clopidogrel-treated patients
were randomized to receive either CGT-2168 (combination
of 75 mg clopidogrel  20 mg omeprazole) or 75 mg
clopidogrel in conjunction with aspirin therapy following
PCI (89). The primary endpoint (6 months upper gastro-
intestinal events) was reduced in the CGT-2168 cohort
(1.1% vs. 2.9% clopidogrel alone). Furthermore, upper
gastrointestinal bleeding was reduced in CGT-2168 treated
patients (0.2% vs. 1.2% clopidogrel alone) and the secondary
outcome measures of all cardiovascular events (composite
occurrence of cardiovascular death, nonfatal MI, coronary
artery bypass graft, PCI, or ischemic stroke), MI, and the
requirement for revascularization procedures were similar
between randomized treatment groups. The investigators
concluded that no clinically relevant adverse interaction
between clopidogrel and PPI treatment was evident (89).
Multiple potential limitations to the COGENT study
should be acknowledged including premature study termi-
nation (planned enrollment 5,000 patients), low cardiovas-
cular event rates (4.9% CGT-2168, 5.7% clopidogrel) and
the lack of either platelet function data (CGT-2168 plus
aspirin vs. clopidogrel plus aspirin) or genotyping in the
study population (94% white).Potential Mechanisms of
Clopidogrel-Omeprazole Interaction
Preliminary in vitro studies suggest intestinal p-glycoprotein
to be the first site of a potential drug-drug interaction (Fig. 3).
Although both omeprazole and clopidogrel are known to
influence p-glycoprotein function, a recent study indicated
that omeprazole (80 mg/day) does not have any effect on
clopidogrel absorption. In addition, evidence that plasma
unchanged clopidogrel levels are not lower during PPI
administration argue against a significant effect of gastric
pH on absorption (77).
The major site of interaction appears to involve hepatic
CYP P450 isoenzymes where both clopidogrel and PPIs
(particularly omeprazole) are extensively metabolized by
CYP2C19 and CYP3A4 (Fig. 3). In vitro studies indicate
that clopidogrel and PPIs inhibit each other’s metabolism
except in poor metabolizers (CYP2C19*2 homozygotes). In
healthy volunteers, omeprazole (80 mg/day) was associated
with a decrease in CL-AM levels and an increase in
VASP-PRI irrespective of clopidogrel dose or time of
treatment. The coadministration of omeprazole (20 to 40
mg/day) with clopidogrel resulted in a moderate (20%)
decrease in clopidogrel-induced platelet inhibition. This
interaction was more pronounced following 7 to 14 days of
therapy (vs. 1 day) and translated into a significant increase
in the prevalence of clopidogrel nonresponders with HPR.
The subsequent reduction in clopidogrel-mediated platelet
inhibition by PPIs may influence clinical outcomes by
shifting more patients into the category of HPR (3). In
support of this hypothesis is the observation that the
relationship between platelet inhibition and the occurrence
of ischemic events is nonlinear (sigmoid) so that relatively
small changes in platelet inhibition may be associated with
more frequent ischemic events in patients who have bor-
derline HPR (90). Moreover, most pharmacokinetic/
pharmacodynamic studies have involved a short duration
(up to 14 days) of observation whereas clinical outcome
studies that have evaluated the PPI-clopidogrel interaction
span much longer periods (1 year). Indeed, the pharma-
cokinetic/dynamic interaction following long-term coad-
ministration is not known.
Alternative Treatment Strategies
In the context that all PPIs are equally effective in gastric
acid suppression with appropriate dosing and that the
pharmacokinetic-pharmacodynamic interaction with clopi-
dogrel is in large part mediated by hepatic CYP P450
isoenzymes (CYP2C19 and CYP3A4), either pantoprazole
(least dependent on CYP metabolism) or rabeprazole (non-
CYP metabolized) may be alternatives for omeprazole.
Another option may be to increase the MD of clopidogrel
during long-term therapy although the efficacy of dose
. Abbr
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377escalation to overcome clopidogrel response variability has
not been established. Moreover, in the PRINCIPLE
TIMI-44 study, a significant pharmacodynamic interaction
between clopidogrel 150 mg daily and omeprazole has been
demonstrated (71). In addition, prasugrel is associated with
greater active metabolite levels (compared with clopidogrel)
and has been shown to overcome clopidogrel nonrespon-
siveness, but may be associated with increased bleeding risk.
A fourth proposed alternative was to separate the timing of
clopidogrel and omeprazole administration. As the plasma
half-lives of both clopidogrel and omeprazole are short (1 to
2 h), the potential for drug-drug competition at CYP2C19
level might be reduced by this strategy. Although the results
of 4 recent studies that evaluated the effect of synchronous
versus staggered coadministration have provoked contro-
versy (76–78), it would appear that the relative “benefit” of
a staggered dose regimen is at best small and may depend on
PPI (especially omeprazole) dose.
A fifth option might involve the nonthienopyridine,
ticagrelor, which does not require metabolic conversion by
hepatic CYP P450 isoenzymes to exert its antiplatelet effect.
The antiplatelet effect of ticagrelor is not influenced by CYP
genetic polymorphisms (91) and clinically significant drug-
drug interactions have not been reported (FDA) (92).
The use of histamine receptor antagonists and/or antacids
may also be considered. The safety and clinical efficacy of
Figure 3. Potential Mechanisms of Drug-Drug Interaction Between Clopido
Based on pharmacogenomics, pharmacokinetics, and pharmacodynamics data,
and clopidogrel are intestinal ABCB1 transporter and hepatic 2C19 isoenzymesH2-receptor antagonist therapy was demonstrated in theFAMOUS (Famotidine for the Prevention of Peptic Ulcers
in Users of Low-Dose Aspirin) trial (93). Finally, in the
updated 2010 American College of Cardiology Foundation/
American College of Gastroenterology/American Heart
Association expert consensus document, PPIs are regarded
as appropriate therapy for patients with multiple risk factors
for gastrointestinal bleeding who require antiplatelet ther-
apy, and routine use is not recommended in patients at
lower risk of upper GIB (94).
Conclusions
Various studies have demonstrated a pharmacokinetic/
pharmacodynamic interaction between PPIs (particularly
omeprazole) and thienopyridines (particularly clopidogrel).
Although several observational studies have suggested that
this interaction may attenuate clopidogrel’s therapeutic ef-
ficacy and may be associated with increased adverse clinical
outcomes, interpretation of these post hoc, nonrandomized
analyses is confounded by covariate imbalance and statistical
bias. After multivariate regression and propensity score
adjustment, the clinical relevance of a clopidogrel-PPI
interaction appears limited (86,87), and no difference in
cardiovascular outcomes was observed between clopidogrel
alone versus clopidogrel plus omeprazole (CGT-2168) in a
single, prematurely terminated randomized clinical trial
nd Omeprazole
ssumed that the major pathways of interaction between omeprazole
eviations as in Figure 1.grel a
is it a(89). Based on the lack of definitive data regarding a
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378clinically relevant interaction between these drugs, it is not
appropriate at this time to recommend termination of PPI
coadministration (including omeprazole) in clopidogrel-
treated patients or to suggest alternative therapeutic strate-
gies. Administration of PPIs (with or without concomitant
clopidogrel treatment) should be guided by the individual
patient’s risk for GIB. In rare situations where significant
concern exists for both GIB and thrombotic complications
(e.g., patient with history of GIB who experiences stent
thrombosis), an assessment of on-treatment (PPI plus
clopidogrel) platelet reactivity may be warranted. A recent
expert consensus document has defined HPR as it corre-
lates with MACE or stent thrombosis using available
techniques including light transmittance aggregometry,
the VerifyNow and Multiplate analyzer point-of-care
assays, and VASP-PRI (2). Definitive recommendations
await the performance and analysis of adequately pow-
ered, prospective randomized clinical trials involving
pharmacodynamic assessments.
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